Nieuws en video's - AROCELL AB UPPSALA ALLPF

Patients treated with Epirubicin and Docetaxel before surgery were followed by their thymidine kinase (TK1) levels in blood to directly observe treatment response. The results show that a TK1-based cell-loss metric after two cycles of therapy predicted the status at the operation after six cycles of chemotherapy. The metric predicted early on whether or not the chemotherapy works. The purpose with this PROMIX study is to investigate whether a cell-loss metric, defined as the ratio between serum...

AroCell AB (publ.) announces today that Peter Löwendahl joins the management team as senior director regulatory affairs. Peter Löwendahl will lead and develop AroCell’s regulatory strategy with focus on the US market and FDA clearance of our TK 210 ELISA. Peter Löwendahl has almost 30 years of experience in quality and regulatory affairs and has previously been responsible for Quality and Regulatory affairs at Elekta AB and global regulatory responsibility for GE Healthcare's Life science...

Word from the CEO “It is with pleasure that I can say that the second quarter of 2019 became one of the most exciting and active quarters in AroCell's history. The goal of establishing AroCell as the given partner and supplier of a reliable method for measuring Thymidine kinase 1 in the blood permeates everything we do. During the quarter, we increased sales, signed more distributor agreements, signed a collaboration agreement with CLIA lab in the US and started a collaboration with the Dana...

Word from the CEO “Biomarkers will play an increasingly important role in how we identify and follow up treatments for patients with cancer in the coming years. The development of an increased individual adaptation of treatment is driven by the use of biomarkers which enable diagnosis of which tumor type the patient has and also what treatment the patient should receive. Thymidine Kinase is an important and exciting biomarker that can provide early detection of therapy response in cancer...

AroCell announces today that we have established a Scientific Advisory Board to support the company in its planned expansion for the coming years. The Scientific Advisory Board (SAB) will have the objective to support the CEO and company in various matters related to AroCell’s expansion in the field of in vitro Diagnostics (IVD). The Scientific Advisory Board will focus on scientific, clinical and regulatory matters relating to AroCell’s expansion into the EU, USA and other new markets. The...

In the corrected version of the press release we have added a link to the article. The aim of the study was to investigate the diagnostic value of the AroCell TK 210 ELISA together with free PSA, pro PSA and PHI in differentiating prostate cancer from benign urological conditions. The study with the title “The combination of AroCell TK 210 ELISA with Prostate Health Index or protease-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous...

The aim of the study was to investigate the diagnostic value of the AroCell TK 210 ELISA together with free PSA, pro PSA and PHI in differentiating prostate cancer from benign urological conditions. The study with the title “The combination of AroCell TK 210 ELISA with Prostate Health Index or protease-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions” is published the peer-reviewed journal “The Prostate” and was performed in...

An abstract from AroCell has been accepted for poster presentation on the American Association of Cancer Research 2019 (AACR 2019) held from March 29 to April 3 in Atlanta, Georgia, USA. The Study compares AroCell TK210 ELISA with TK-Liaison assay. The study entitled “ The Assay of Thymidine Kinase 1 in Sera from Subjects with Hematological and Solid Tumors with AroCell TK 210 ELISA: Comparison with TK-Liaison Assay and its Clinical Implications ” by Jagarlamudi KK et al. shows that the...

The study with the title “The combination of AroCell TK 210 ELISA with Prostate Health Index (PHI) or PSA density can improve the ability to differentiate prostate cancer from non-cancerous conditions” will be published in the peer-reviewed journal “The Prostate”. The link to the article will be made available during March when the article has been published. The aim of the study was to investigate the diagnostic value of the AroCell TK 210 ELISA together with free PSA, pro PSA and PHI...

Word from the CEO ”2018 has been an exciting year for AroCell with several major events. In April, AroCell signed a global non-exclusive license agreement with F. Hoffmann-La Roche Ltd (Roche). Roche is the market leader in diagnostics and the diagnostics part of the company has sales of just over SEK 100 billion and a global market share of around 20%. The license agreement gives Roche global sales rights for which AroCell receives royalties from future sales. Through the license agreement...

Today AroCell is launching its new website. The goal with the new website is to facilitate for our customers, business partner, and investors to find relevant information about AroCell. The website (arocell.com) informs about precision monitoring in cancer care and the potential clinical utility of measuring the concentration of TK1 during cancer treatment. Thymidine kinase 1 (TK1) is a potential biomarker during cancer treatment. The determination of the TK1 concentration in serum is simple...

AroCell AB (publ) announced today that a distribution agreement has been signed with the Beijing based company Gongyingshi for the promotion and distribution of the AroCell TK 210™ ELISA in China. The pharmaceutical and biotechnological industries are growing rapidly in China making it an attractive market for innovative biomarker assays such the AroCell TK 210 ELISA. Our TK 210 ELISA measures concentration levels of thymidine kinase 1 (TK 1) in blood samples and provides valuable information...

AroCell AB (publ) announced today that a distribution agreement has been signed with the French company Eurobio Scientific, for distribution of AroCell TK 210 ELISA in France and Switzerland. AroCell TK 210 ELISA measures thymidine kinase 1 (TK1) levels in serum and provides valuable information about cell proliferation and disruption. As cancer tumors have increased cell proliferation and successful treatment disrupt cancer cells, the use of AroCell TK 210 ELISA for patient monitoring during...

A peer-reviewed article has been published in the journal Nucleosides, Nucleotides and Nucleic Acids, entitled “Doxorubicin effects on leukemia and breast cancer cells in culture on the Thymidine Kinase 1 protein levels using AroCell TK 210 ELISA: a tool for drug development”, written by Kiran Jagarlamudi et al. The results have previously been presented at a scientific meeting in Gdansk last year. TK 1 has the potential as a proliferation and cell disruption biomarker for the monitoring of...

AroCell announced today that the U.S. Patent and Trademark Office has granted AroCell´s patent US 10,100,128 titled ”Monoclonal Anti-TK1 Antibodies”. The patent refers to AroCell’s proprietary monoclonal antibodies that enable the specific and sensitive measurement of Thymidine Kinase 1 in blood. ” We are delighted that the U.S. Patent and Trademark Office has granted the US patent. This reinforces our patent position in the U.S. and increases AroCell's attractiveness as business...

AroCell AB announces today that a second abstract has been accepted by ISOBM ( International Society of Oncology and BioMarkers) for poster presentation at the annual meeting in Hamburg, Germany November 24-27, 2018. The study, entitled “ Molecular forms of serum thymidine kinase 1 in hematological malignancies determined with the AroCell TK 210 TM ELISA,” confirms the importance and significance of using AroCell’s proprietary sample dilution buffer included in TK 210 ELISA for...

An abstract entitled “A performance evaluation of three currently used thymidine kinase 1 assays in sera from patients with hematological malignancies shows high concordance” , by Staffan Eriksson et al., has been accepted for oral presentation at the ISOBM ( International Society of Oncology and BioMarkers) congress in Hamburg, Germany November 24-27, 2018. The study presents results from a performance evaluation of TK 210 ELISA and activity-based methods, e.i. LIAISON ® Thymidine Kinase,...